Hangzhou, April 24, 2026 — WinHealth Pharma was named to the 2026 Hangzhou Unicorn & Semi-Unicorn Enterprise List at the 10th All Blossom Conference, marking its sixth consecutive year on the list. This recognition reflects WinHealth Pharma’s sustained momentum in the healthcare sector and strong growth driven by its strategic planning, resource integration and commercialization.
As a key barometer of China’s innovation economy, the All Blossom Conference is jointly organized by the Zhejiang Provincial Committee of the China National Democratic Construction Association, Zhejiang Chamber of Commerce, and the China Investment Development Promotion Association. Its annual lists focus on strategic sectors such as life sciences and healthcare, recognizing companies with strong growth potential and technological capabilities.
WinHealth Pharma Recognized as a Hangzhou Semi-Unicorn Enterprise for the Sixth Year
Since the beginning of 2026, WinHealth Pharma has achieved a number of important milestones across its business development and product portfolio:
- Recognized as 2026 Top Employer in China, reflecting continued progress in organizational and talent development
- Entered into a strategic partnership with Jacobson Pharma Group, introducing ARSENOL® to further strengthen its hematology product portfolio
- Received approval in China for Kapruvia®, further reinforcing its presence in kidney disease treatment
Jack Wang, Chairman of WinHealth Pharma, said, “Being listed on the Hangzhou Unicorn & Semi-Unicorn Enterprise List for six consecutive years reflects our overall capabilities, as well as the progress we have made in advancing our product portfolio and business development. As the global pharmaceutical industry continues to evolve rapidly, we will bring high-quality global innovation to China, stay focused on major diseases areas including kidney and hematologic diseases, and accelerate the introduction of high-quality therapies to address patients’ clinical needs. At the same time, building on Hangzhou’s increasingly supportive innovation ecosystem, we will further strengthen our development and commercialization capabilities, deepen our global footprint, and build a globally competitive product portfolio as we continue to advance on our path of high-quality growth.”
About WinHealth Pharma
WinHealth Pharma is a China-based integrated pharmaceutical company with a core focus on kidney diseases and strategic expansion into hematology and other major therapeutic areas. It possesses comprehensive capabilities across the entire pharmaceutical value chain from research and development to manufacturing and commercialization. Guided by its “Patients-First” philosophy and the mission of “Advancing Health, Empowering Lives,” the company is dedicated to improving patients' quality of life through innovative therapies. By leveraging a multi-strategy-driven business model, WinHealth Pharma connects with global innovations to continuously build a diverse, differentiated, and highly competitive product portfolio. Anchoring a strong presence in China, the company is actively expanding into other Asian markets and key international regions, including Switzerland and Japan. WinHealth Pharma is committed to fostering an open and collaborative healthcare ecosystem, driving industry innovation to meet the evolving needs of patients worldwide. For more information, please visit www.winhealth.hk.